Standard BioTools to sell microfluidics business to Archimed
Standard BioTools Inc. has announced an agreement to sell its microfluidics business to Archimed. The deal is expected to close in approximately 30 days, during which time the microfluidics business will continue to operate as part of Standard BioTools.
Oct. 5 (Reuters) — Standard BioTools Inc said it has agreed to sell its microfluidics business to Archimed. The company said the deal is expected to close in about 30 days. Until the transaction closes, the microfluidics business will continue to operate as part of Standard BioTools.